Guardant Health Partners with Patrick Dempsey to Promote 93% Shield Test Completion
Guardant Health has enlisted actor Patrick Dempsey to drive awareness of its FDA-approved Shield blood test for adults 45+, registering a 93% test completion rate across 100,000 orders. The Shield test’s inclusion in NCCN colorectal cancer guidelines could expand access among the 54 million Americans avoiding conventional screenings.
1. Partnership Details
Guardant Health has partnered with actor and cancer advocate Patrick Dempsey to raise public awareness during Colorectal Cancer Awareness Month. Leveraging Dempsey’s personal advocacy and the founding of The Dempsey Center, the campaign highlights his experience using Shield and emphasizes the importance of early, noninvasive screening for adults aged 45 and older.
2. Shield Test Performance and Regulatory Approvals
Shield is the first blood-based colorectal cancer screening test approved by the FDA in 2024 and recently incorporated into National Comprehensive Cancer Network guidelines. Real-world data show a 93% completion rate across the first 100,000 tests ordered, significantly improving adherence compared with traditional methods.
3. Market Opportunity and Growth Prospects
More than 54 million Americans aged 45 and over avoid recommended colorectal screenings due to invasiveness and inconvenience of existing options. With results in two weeks from a routine blood draw and early detection boosting five-year survival to over 90%, Shield could capture a sizeable share of the under-screened population and drive new revenue streams for Guardant Health.